Blood Substitutes and Oxygen Biotherapeutics by Liu, Henry; Kaye, Alan D.; Jahr, Jonathan S.;

Long description:

"

The second edition of Blood Substitutes delivers a comprehensive and authoritative update on the rapidly evolving field of artificial oxygen therapeutics and next‑generation blood products. Building on the foundation of the first edition, this volume expands its scope to include the latest scientific advances and innovative approaches that are reshaping transfusion medicine. From hemoglobin‑based and perfluorocarbon‑based oxygen carriers to engineered proteins, vesicles, and nanotechnologies, the book offers an in‑depth exploration of the most promising solutions to global blood supply challenges.

A significantly expanded set of chapters on plasma, platelets, and hemostasis reflects the fast-growing importance of novel blood product development. Readers will find expert coverage of lyophilized plasma, freeze‑dried platelet hemostatic technologies, cryopreserved platelets, and the regenerative and immunologic properties of plasma-based therapies. These insights highlight both the scientific innovation and clinical potential driving the next generation of trauma, perioperative, and critical care interventions.

With contributions from leading investigators and clinician‑scientists, this edition integrates foundational biochemistry with translational research, regulatory considerations, and real-world applications. Detailed analyses of cutting-edge agents equip readers with a clear understanding of current evidence, safety profiles, and therapeutic opportunities.

Designed for a wide clinical and scientific audience, Blood Substitutes, 2nd Edition serves as an essential reference for professionals in surgery, anesthesiology, obstetrics and gynecology, trauma care, hematology/oncology, cardiology, pediatrics, critical care, and military medicine. Whether used for research, education, or clinical decision-making, this volume offers a definitive and forward‑looking guide to the future of blood replacement and oxygen biotherapeutics.

Table of Contents:

Biochemistry of Hemoglobin and Hemoglobin-Based Oxygen Carrier.- Platelet Mimicry for Biomechanical Function.- HBOC Impact Upon Vasoactive Effectors, Rheology and Blood Flow.- Recombinant Hemoglobins with Enhanced Oxydative Stability.- Nitric Oxide Protectants as a Potential Adjunct of HBOCs.- Non-hemoglobin Engineered Protein Oxygen Carriers: Omniox.- Metal-Organic Framework-Based Oxygen Carriers.- Coupled Cross-Linked Human Hemoglobins (Bis-Tetramers) Overcome HBOC Problems.- Hemoglobin-based Oxygen Carriers, Oxidative Stress and Myocardial Infarction – Issues and Implications for HBOC Development.- Fractionated Polymerized Hemoglobin-A Modernized Erythrocytic Substitute and Oxygen Biotherapeutic.- Hemoglobin-Based Oxygen Carriers: Toxicity Mechanisms and Molecular Mitigation Strategies.- Nitric Oxide and Hemoglobin: physiological implications.- Ideal P50: The Ability to Design Artificial Oxygen Carriers and to Create a Product that Self Regulates.- Hemoglobin-Based Oxygen Carriers: Evolving Concepts and Clinical Implications.- HBOC Design Using Protein Engineering.- Pegylated Bovine Hemoglobin: Manufacturing and Characterization.- Benefits and risks of encapsulated Hb as an artificial oxygen carrier.- Cardiovascular Effects of Hemoglobin-Based Oxygen Carriers.- Perfluorocarbon-based Oxygen Carriers: A Comprehensive Overview.- Expanded Access when Blood Not an Option: Use of Hemopure and Sanguinate.- Perfluorocarbon-based artificial oxygen carriers for kidney and heart perfusion.- Perfluorocarbon-based Artificial Oxygen Carriers for Ex Vivo Organ Perfusion.- The Erythrocruorins as Synthetic Blood Products: What Is New?.- Whole Blood vs Blood Component Therapy.- Biosynthetic Blood Components: Use Case for Hemorrhagic Shock and Clinical Trial Design.- Phase I clinical trial of hemoglobin vesicles (HbV).- Blinded, Randomized, Controlled Trials of HBOC-201 (Hemopure).- Clinical Development and Therapeutic Applications of Clinical Development and Therapeutic Applications of SANGUINATE (PP-007).- Real-Time Circulating Blood Volume Measurements Using Hemoglobin-based Oxygen Carriers: A Novel Alternative to Traditional Methods.- YQ23: A New Hemoglobin Based Oxygen Carrier in Critical Limb Ischemia — Phase I/II Trials.- The Therapeutic Potential of Plasma Extracellular Vesicles.- Pathogen Reduction for Novel Blood Product Development.- Prothrombin Complex Concentrate as a Therapeutic in Trauma.- The Regenerative Properties of Plasma in Burns.- The Role of Cryoprecipitate in Trauma-Induced Hemorrhagic Shock and Endotheliopathy.- Plasma versus Factor Concentrates Therapy.- The Endotheliopathy of Trauma Patients with Plasma Product Transfusion: Emerging Clinical Developments.- Solvent/Detergent-Treated Pooled Plasma Products and Factor Concentrates.- Freeze Dried Plasma.- Platelets-Fibrin-RBC Interactions in Hemostatic Clots.- Apheresis Platelet Product Functional Variability.- SynthoPlate and Related Platelet-Inspired Synthetic Nanotechnologies for Hemorrhage Control.- Blood Substitutes Related Regulatory Updates (FDA/CBER).- Innovative Pre-Clinical Models to Prepare Products for FDA Review.- The Regulatory Challenges of Producing Dried Plasma or What’s a Regulator to Do?.- The addition of a simple aqueous solution of synthetic neocatalase, neosuperoxide dismutase and neocarbonic anhydrase improve the effectiveness of oxygen carriers for the preservation of warm ischemic cell/tissue.- A Military-Civilian Partnership Model to Advance Commercialization of Blood Products.- Acute Safety Study of the Intravenous Injection of a Lyophilized Form of an Extracellular Hemoglobin, M101, in the Rat.